Prescient expands PTX-200 trial after it eradicates cancer completely
Category: #health  By Mateen Dalal  Date: 2019-11-29
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Prescient expands PTX-200 trial after it eradicates cancer completely

Prescient Therapeutics, a renowned small molecule drug development firm aimed at developing new cancer therapies, reportedly announced that it is extending its Phase 1b trial in patients with AML (acute myeloid leukemia) after the disease was completely eradicated from three participating patients.

The clinical stage firm was treating 15 patients with refractory or relapsed AML using its novel drug PTX-200. Refractory or relapsed cancers are usually hard to treat as they are extremely resistant and do not respond effectively to therapy.

PTX-200 is a new PH domain inhibitor that stops a vital tumor survival pathway that is known as Akt. The Akt pathway plays a crucial role in cancer development including breast, leukemia and ovarian cancer.

PTX-200 is also being examined in an ongoing Phase 2 trial in patients with breast cancer and also in a Phase 1b study in patients with persistent platinum-resistant or recurrent ovarian cancer.

The three patients whose cancer was completely eradicated received 25-35 milligrams per square meter of PTX-200 in combination with 200 to 400 mg/m2 of cytarabine chemotherapy agent.

Dr. Terrence Chew, Chief Medical Officer at Prescient stated that these three complete responses are highly encouraging for a hard-to-treat cancer patient demographic. After it consults with study investigators, the company plans to carry out a protocol amendment to alter the PTX-200 dosing schedule in relation to the dosing of cytarabine. The change aims to minimize overlapping drug interactions. Through this protocol amendment, the company looks to get more participants through more therapy cycles with an aim to expand upon these responses.

Dr. Chew further added that the company’s investigators are highly supportive towards these amendments since they are being encouraged by the outcomes in this patient population, which is very hard to treat and presently has very few treatment options.   

Prescient further added that the amendment would go through the general FDA and ethics committee study and reviews. The company expects to re-start new patient enrolment soon in 2020.

 

Source credit: https://smallcaps.com.au/prescient-therapeutics-expands-study-completely-eradicating-cancer-in-patients/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Lufthansa Group to swap old A340 planes with 10 new long-haul jets

Lufthansa Group to swap old A340 planes with 10 new long-haul jets

By Mateen Dalal

The parent company of German airline Deutsche Lufthansa AG, Lufthansa Group, reportedly said it would purchase a total of 10 long-haul aircraft, including 5 Boeing B787-9s and 5 Airbus A350-900s, to replace aging Airbus A340 planes in an effort to mo...

Facebook, Google sign content deals with Australia’s Seven West Media

Facebook, Google sign content deals with Australia’s Seven West Media

By Mateen Dalal

Seven West Media, an Australian newspaper and television firm, has reportedly signed a content deal with Facebook Inc. and Google LLC in the wake of recent landmark laws that have enabled the industry to obtain new revenue sources and adapt to the in...

Microsoft considered reducing Xbox Store fee to revive console gaming

Microsoft considered reducing Xbox Store fee to revive console gaming

By Mateen Dalal

Multinational tech-giant Microsoft was reportedly looking to lower its Xbox store commission fee to a meager 12% from the previous 30%, as per confidential documents submitted in the Epic Games and Apple case. The document from January also contains...